Metrics as of 10/14/2026, 02:13 PM (Berlin time), refresh in progress.
Ionis Pharmaceuticals Stock
Ionis Pharmaceuticals, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Brett Monia
- Employees
- 1,480
- Market cap
- $7 B
- IPO
- 17/05/1991
Founded in 1989 and headquartered in Carlsbad, USA, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company operating within the Healthcare sector. The company specializes in the discovery and development of RNA-targeted therapies. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Ionis Pharmaceuticals stock: price history
1D
-3.0%
1W
-3.7%
1M
-21.8%
6M
-44.8%
YTD
-46.4%
1Y
-40.0%
2Y
+10.2%
5Y
+24.3%
10Y
+46.1%
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~11% weaker price swings than usual
Ask the agents about Ionis Pharmaceuticals
Analyst assessment of Ionis Pharmaceuticals
PRICE TARGET LOW
US$54.00
CONSENSUS
US$84.08
MEDIAN
US$85.00
PRICE TARGET HIGH
US$115.00
1
STRONG BUY
18
BUY
14
HOLD
0
SELL
0
STRONG SELL
33
TOTAL · Buy
As of: 24/09/2026
Ionis Pharmaceuticals stock metrics
P/E
-12.25
P/B
15.94
EV/EBITDA
-18.99
RETURN ON EQUITY
-26.1%
NET MARGIN
-42.8%
DEBT/EQUITY
5.5
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
98.0%
FLOAT SHARES
162,926,959
AVG. DAILY VOLUME (30D)
4,035,748
Insider transactions (SEC)
Monia Brett P
Birchler Brian
BENNETT C FRANK
O'NEIL PATRICK R.
Hayden Michael R
Institutional holders
Comparable stocks
Frequently asked questions about Ionis Pharmaceuticals stock
What does Ionis Pharmaceuticals do?
Ionis Pharmaceuticals, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Brett Monia, the company employs around 1,480 people.
The IPO was on 17/05/1991; the stock trades on NASDAQ under the ticker IONS.
What do analysts say about Ionis Pharmaceuticals stock?
33 analysts rate the stock, the consensus is Buy (as of 24/09/2026).
The average price target is US$84.08, ranging from US$54.00 to US$115.00, with a median of US$85.00.
This is an external assessment, not a statement by Market Jury.
When does Ionis Pharmaceuticals report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly -11% stronger than usual.
Does Ionis Pharmaceuticals pay a dividend?
No, Ionis Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Ionis Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Ionis Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Ionis Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.